top of page

AZBio: Avery Therapeutics Completes Successful Pre-IND Meeting with FDA for MyCardia

We are so excited for Avery Therapeutics for successfully completing a Pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA). Avery received FDA feedback on its planned manufacturing and IND-enabling studies for its novel therapeutic candidate, MyCardia™, which is a treatment in development for ischemic heart failure. Read the whole press release here!


Avery was the 2016 Mainstage Prize Winner at IdeaFunding. We are thrilled to see them continue their awesome and impactful journey.

78 views0 comments

Comments


bottom of page